Biotech: Page 7
-
How pharma leaders talk about ethics in a highly criticized industry
The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?
By Michael Gibney • Nov. 9, 2023 -
Deep Dive
What if a CRISPR cure isn’t such an easy choice?
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023 -
Trendline
Oncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
An at-home flu vaccine? If approved, it could open the door to more DIY options
A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.
By Kelly Bilodeau • Nov. 8, 2023 -
Biotech Spotlight
A new delivery method muscling its way into the RNA space
With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.
By Kelly Bilodeau • Nov. 8, 2023 -
Q&A
23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.
By Alexandra Pecci • Nov. 7, 2023 -
Opinion
The thorniest questions facing pharma, according to a leading bioethicist
Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.
By Michael Gibney • Nov. 6, 2023 -
PharmaVoice 100
PharmaVoice 100s: Entrepreneurs
From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.
By Meagan Parrish • Nov. 3, 2023 -
In a record year for biotech bankruptcy, here are 3 companies that went under
A challenging funding environment and lack of partnering deals have contributed to the market's ongoing troubles.
By Alexandra Pecci • Nov. 2, 2023 -
Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls
From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.
By Kelly Bilodeau • Nov. 1, 2023 -
What’s next for COVID dark horse Novavax?
Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?
By Kelly Bilodeau • Oct. 30, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
By Meagan Parrish • Oct. 27, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Dr. Jeremy Levin, a transformational leader
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
By Michael Gibney • Oct. 27, 2023 -
The 2023 Red Jacket honorees
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
By Meagan Parrish • Oct. 27, 2023 -
Biotech Spotlight
Cidara’s J&J-partnered immunotherapy could target flu and cancer
On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.
By Alexandra Pecci • Oct. 26, 2023 -
Patient groups have become a powerhouse in R&D. Here’s a look at their impact.
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
By Kelly Bilodeau • Oct. 25, 2023 -
Pfizer’s new shot approval adds to a growing vaccine prowess
Pfizer brought in a new approval for a five-in-one shot for meningococcal disease, and the company has built a sizable vaccine business over time.
By Michael Gibney • Oct. 24, 2023 -
Biotech Spotlight
An ‘inverse vaccine’ takes aim at autoimmune diseases
Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.
By Kelly Bilodeau • Oct. 23, 2023 -
From the rainforest to Wall Street — Jaguar Health’s big play for revitalization
A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.
By Kelly Bilodeau • Oct. 17, 2023 -
The top biopharma conferences in 2024
A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.
By Ned Pagliarulo • Oct. 16, 2023 -
PharmaVoice 100
PharmaVoice 100s: Rare disease warriors
Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.
By Michael Gibney • Oct. 16, 2023 -
Has the science of anti-aging caught up with the dream of a longer life?
Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.
By Kelly Bilodeau • Oct. 16, 2023 -
Opinion
Branded: The trademarks pharma leaders look up to
What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.
By PharmaVoice Staff • Oct. 13, 2023 -
Deep Dive
A decade later, biotech’s CRISPR revolution is still going strong
Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.
By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023 -
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.
By Michael Gibney • Oct. 12, 2023 -
Q&A
5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
By Meagan Parrish • Oct. 11, 2023